Secukinumab is a specific
neutralizing antibody for
IL-17A. At present, numerous studies have confirmed the important role of
IL-17A in
sepsis, but the role of
secukinumab in
sepsis has not been studied. The present study explored the protective effect and underlying mechanism of
secukinumab in
severe sepsis model rats. We established a
severe sepsis rat model using cecal
ligation and
puncture (CLP). The optimal dose of
secukinumab was determined by observing the 7-day survival rate of
severe sepsis model rats. The expression levels of TNF-α,
IL-6, and
IL-17A in plasma and lung tissue were determined by
enzyme-linked
immunosorbent assay. The degree of pathological damage to lung tissue was evaluated by
hematoxylin-
eosin (H-E) staining and pathological damage scale. The expressions of IKBα/NFκB pathway
proteins and downstream-related inflammatory factors were detected by western blotting and real-time quantitative polymerase chain reaction (RT-qPCR). Our results show that high-dose
secukinumab can inhibit the activation of the IKBα/NFκB inflammatory pathway by neutralizing
IL-17A and reducing the gene expression of pathway-related inflammatory
cytokines, thereby reducing the levels of inflammatory
cytokines in lung tissue and plasma, thereby reducing the damage of lung tissue in
severe sepsis model rats and improving the systemic inflammatory response.